THYROCARE558.00

Thyrocare Technologies Ltd.

· Pharma & Health
₹ CrorePeersLALPATHLABMETROPOLISVIJAYASUPRIYAVIYASHSTARSPARCYATHARTHMcap ₹8,882 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
THYROCARE
FY26
LALPATHLAB
FY26
METROPOLIS
FY26
VIJAYA
FY26
Peer
Median
Valuation — at last close
P/E54.33×63.23×64.74×89.41×64.74× -16%
P/B15.15×12.61×8.09×16.16×12.61× +20%
EV/EBITDA33.17×40.10×30.33×45.10×40.10× -17%
Market Cap₹8,882 Cr₹32,045 Cr₹12,336 Cr₹15,465 Cr₹15,465 Cr -43%
Growth
Revenue CAGR 3Y16.33%11.06%12.75%21.03%12.75% +28%
Revenue CAGR 5Y10.88%11.81%10.52%16.66%11.81% -8%
Net Income CAGR 3Y36.27%28.35%10.06%26.62%26.62% +36%
Revenue YoY (latest Q)24.34%19.10%16.62%22.83%19.10% +27%
Net Income YoY (latest Q)34.06%27.24%25.72%37.61%27.24% +25%
Profitability
EBITDA Margin31.61%28.32%24.36%41.38%28.32% +12%
Net Income Margin19.64%18.45%11.62%21.24%18.45% +6%
Return on Common Equity27.82%19.86%12.46%18.07%18.07% +54%
Return on Capital Employed31.92%23.03%14.81%17.72%17.72% +80%
Return on Assets21.79%16.20%8.94%11.48%11.48% +90%
Credit & Quality
Total Debt/Equity0.00×0.00×0.01×0.00×0.00×
Interest Coverage72.66×27.22×10.88×7.38×10.88× +568%
Scale — latest FY
Revenue / Total Income₹829 Cr₹2,763 Cr₹1,646 Cr₹814 Cr₹1,646 Cr -50%
Net Income₹163 Cr₹510 Cr₹191 Cr₹173 Cr₹191 Cr -15%
Total Assets₹747 Cr₹3,146 Cr₹2,138 Cr₹1,507 Cr₹2,138 Cr -65%
EPS₹10.27₹30.24₹9.19₹16.81₹16.81 -39%
Book Value per Share₹36.82₹151.63₹73.53₹93.02₹93.02 -60%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.